

Soap: the science behind it, the changing regulations ahead, and tools and tips for selecting a hand soap that's right for your facility.

Megan J. DiGiorgio MSN, RN, CIC, FAPIC



Introduction

Hand hygiene is the primary measure to prevent transmission of pathogens in healthcare facilities¹ and alcohol-based hand rub (ABHR) is designated as the preferred method for performing hand hygiene by the 2002 Centers for Disease Control and Prevention (CDC) and the 2009 World Health Organization (WHO) hand hygiene guidelines. However, soap and water also plays a critical role in hand hygiene, namely when hands are visibly soiled or contaminated with blood or other bodily fluids and when there are outbreaks of *Clostridium difficile* or Norovirus.²

Because ABHR has been the primary focus for hand hygiene, soap has received less attention in recent years, and due to limited data around soap, many healthcare facilities have given less thought to the type of soap they are using. However, regulations for antiseptic active ingredients typically used in hand soap are undergoing revisions and the landscape of available actives is likely to change soon. These forthcoming regulatory changes will force many healthcare facilities to rethink their hand soap choices and look for technical information that typically does not exist.

Because ABHR has been the primary focus for hand hygiene, soap has received less attention in recent years, and due to limited data around soap, many healthcare facilities have given less thought to the type of soap they are using. However, regulations for antiseptic active ingredients typically used in hand soap are undergoing revisions and the landscape of available actives is likely to change soon. These forthcoming regulatory changes will force many healthcare facilities to rethink their hand soap choices and look for technical information that typically does not exist. Anticipating these changes and arming oneself with information can help alleviate uncertainty and simplify future decisions. The purpose of this paper is to educate infection preventionists and other key decision makers on the science of soap, help explain the regulatory changes underway, understand possible outcomes, provide guidance on how to evaluate soap products, and decide which soap is best for a facility.

Background

Prior to publication of the 2002 CDC hand hygiene guidelines, soap was the predominant hand hygiene product. Today, alcohol-based hand rub (ABHR) represents about two-thirds of all hand hygiene product sales in healthcare.³ While ABHR is the primary pillar of hand hygiene due to its many proven advantages such as superior efficacy, speed of procedure, better compliance, and skin health benefits,⁴ soap remains an important aspect of the hand hygiene regimen that is not always given as much consideration as it deserves.

The Science of Soap

Soap's Mechanism of Action

When selecting the type of soap for a healthcare facility, it's important to first understand how soap works. The general mechanism of action is lifting and suspending oil, dirt, and other organic substances from hands so they can be rinsed down the drain, much like cleaning a dirty dish. Alkali metal salts of fatty acids, such as sodium laurate and potassium cocoate, are traditionally used as soaps. Soaps are classified as surfactants (surface active agents) as they possess both polar (ionic/hydrophilic) and non-polar (long hydrocarbon/hydrophobic) groups. When soap is added to water, tiny clusters called micelles are formed due to aggregation of hydrophobic segments. The ionic segments of surfactants orient outward of the core aggregates/micelles. Hydrophobic segments of micelles have strong affinity towards oil-type dirt and germs, and the hydrophilic segments of micelles attract toward the water-soluble materials. As a result, soaps are capable of cleaning skin and other substrates by removing both water soluble and water-insoluble dirt from the substrates and suspending them in aqueous solutions.

In recent decades, detergents have also been used as soaps. Detergents have similar functional groups as soaps but their hydrophilic groups can be of various types including anionic, non-ionic, cationic, or amphoteric, instead of carboxylic salts. Examples of detergents include sodium laureth sulfates, alkyl polyglucosides, cocamidopropylbetaine and fatty alkyl amine oxides.

With plain or non-antimicrobial soaps, organic substances and some microorganisms on the skin are removed, but the commensal resident organisms that are reduced quickly regrow to a normal level. The target organisms for removal are transient, non-resident organisms that may cause illness. Antimicrobial soaps also contain an antibacterial active ingredient that interacts with and kills bacterial cells. Some actives (e.g. chlorhexidine gluconate or CHG) may deposit on the skin's surface in low levels, which keeps the number of microorganisms to a reduced level by static activity for an extended period of time. There are several active ingredients that are used in antimicrobial soap formulations in healthcare, and their spectrum of activity and efficacy against microorganisms varies and can be greatly affected by the other non-active ingredients in the formula (**Table 1**).

variables, cost, and reasons of practicality. However, studies of germ reduction on the hands support that ABHR is most efficacious, followed by antimicrobial soap, followed by non-antimicrobial soap as least efficacious (**Table 2**).¹ That said, healthcare facilities are permitted the choice between antimicrobial and non-antimicrobial soap, or may use a combination of the two.

A good way to approach the decision of whether to choose an antimicrobial or a non-antimicrobial soap is to consider risk reduction. **Table 3** shows comparisons of the average log₁₀ reductions against bacteria after a single hand wash using water, non-antimicrobial soap, and antimicrobial soap. The greatest risk reduction will be achieved by using an antimicrobial soap. For example, if a healthcare

Table 1. Active Ingredients Commonly Used in Soaps and Sanitizers Today and Their Spectrum of Activity

Product Type	Active Ingredient	Gram + activity	Gram - activity	Viral activity Enveloped/ Non-enveloped	Fungal activity	Currently Monograph Ingredient
Sanitizer	Ethyl alcohol	+++	+++	+++ / ++	+++	Yes
Soap	Triclosan	+++	+	+ / ?	±	Yes
	Chloroxylenol (PCMX)	+++	+	+ / ±	+	Yes
	Quaternary ammonium compounds (quat)	++	+	+ / ?	±	Yes
	Chlorhexidine gluconate (CHG)	+++	++	++ / +	+	No; requires NDA


Good = +++, moderate = ++, poor = +, variable = ±, none = -, unknown = ?

Adapted with permission from Pittet, Allegranzi & Sax, 2007.⁴⁷⁹ WHO Guidelines on Hand Hygiene in Health Care: First Global Patient Safety Challenge Clean Care Is Safer Care. Geneva: World Health Organization; 2009.

Lack of Consensus around Antimicrobial versus Non-antimicrobial Soap

Both CDC and WHO hand hygiene guidelines allow the use of either an antimicrobial or a non-antimicrobial soap, and due to a lack of evidence demonstrating clinical benefit (i.e. resulting reduction of infection rates), do not recommend one over the other. Clinical data are lacking due to complexity of designing such a study, difficulty eliminating confounding

Table 2. Relative Efficacy of Different Hand Hygiene Preparations



worker's (HCW) hands are contaminated with 10,000 bacteria and he or she were to wash with plain water only, a 1 log₁₀ reduction would be achieved, leaving 1,000 bacteria behind. Non-antimicrobial soap would result in around a 2 log₁₀ reduction and would leave 100 bacteria behind. Washing with an antimicrobial soap would result in around a 2.5 to 3 log₁₀ reduction, resulting in between 10 and 30 bacteria remaining on the hands. Depending on the organism, the difference between exposure to 10 to 30 bacteria versus 100 bacteria could potentially mean the difference between acquiring an infection or not. Therefore, facilities seeking the highest level of risk reduction should choose an antimicrobial soap.

average from as little as 6.6 seconds to as much as 30 seconds.⁵ In addition, HCW often failed to cover all surfaces of their hands and fingers highlighting the fact that there is a need for education around proper technique.

Soap's Effects on Skin

Even though ABHR is positioned as the most efficacious and mildest hand hygiene approach, ABHR are

Soap is still a critical component of a hand hygiene program and should be used when hands are visibly soiled or contaminated with blood or other bodily fluids, before eating, and after using the restroom.

Table 3. Average Log₁₀ Reductions of Different Hand Washing Preparations

Product Type	Average Log Reductions Against Bacteria	If 10,000 Bacteria on Hands, How Many CFU* Remain on Hands	If 1,000 Bacteria on Hands, How Many CFU* Remain on Hands
Water	1.00	1,000	100
Non-Antimicrobial Soap	~2.00	100	10
Antimicrobial Soap	2.50-3.00	10-30	1-3

*CFU, Colony-forming units

Handwashing Technique

While there's a lack of consensus on type of soap, there's more consensus around handwashing technique. The CDC recommends wetting hands first with water, applying a manufacturer-recommended volume of product to hands, and rubbing vigorously for at least 15 seconds, covering all surfaces of the hands and fingers, followed by rinsing and drying thoroughly with a disposable towel. The WHO recommends a similar method, although they provide more specifics when it comes to vigorously rubbing all surfaces of hands and fingers, separating the process into very specific steps such as palm to palm, fingers interlaced, rotational rubbing of thumb and so forth. Despite published recommendations, HCW have been observed not rubbing for an adequate amount of time. In ten observational studies, the duration of handwashing ranged on

not intended or effective at removing visible soil from hands. Soap is still a critical component of a hand hygiene program and should be used when hands are visibly soiled or contaminated with blood or other bodily fluids, before eating, and after using the restroom. Many healthcare facilities also mandate soap and water use when caring for patients with *C. difficile*. In all other clinical situations, an ABHR should be used for routine decontamination of hands.

HCW skin health is an important factor affecting hand hygiene compliance and there is a perception that ABHR cause skin damage. But, if ABHRs are properly formulated, soap and water use is generally the main factor affecting skin condition with current hand hygiene products today.

hygiene compliance and there is a perception that ABHR cause skin damage. But, if ABHRs are properly formulated, soap and water use is generally the main factor affecting skin condition with current hand hygiene products today. It is well known that washing with soap, specifically surfactants, can damage the skin's barrier. The stratum corneum (SC) is the very top layer of skin and it can be described using a "brick and mortar" model. Under a microscope, the skin barrier, when healthy, looks like a brick wall. The "bricks," are called corneocytes, which are really dead skin cells. They are held in place by a lipid bilayer and moisture which is the "mortar." The lipid bilayer is composed of two layers of fatty acids. Its role is to help "lock in" moisture.

There is a science to properly formulating soap, and poorly formulated soaps will be very harsh on the skin. As they lift the dirt, they will also remove natural components of the skin (corneocytes and lipids) that help keep skin healthy. This sets up a vicious dry skin cycle that worsens with each soap insult or wash.

There is a science to properly formulating soap, and poorly formulated soaps will be very harsh on the skin. As they lift the dirt, they will also remove natural components of the skin (corneocytes and lipids) that help keep skin healthy. This sets up a vicious dry skin cycle that worsens with each soap insult or wash. Finally, any insult to the SC barrier then leads to an increase in epidermal nerve density that can cause sensations of stinging, burning, itching, tingling and tightness. This is often recognized during contact with ABHR, but it is the soap, specifically surfactants, that created the condition. In addition, environmental stressors such as low relative humidity, using hot water, and low quality of paper towels can also affect the skin.⁶ Therefore, it is critical to provide the right product formulation to minimize damage and keep the "bricks and mortar" intact. These tightly packed "bricks" help restore the skin's natural protection against the environment, chemicals, and pathogens.

As discussed earlier, antimicrobial soaps remove dirt, oil, and organic substances from the skin; however, they also have the addition of an active ingredient to help kill germs. Traditionally, antimicrobial soaps have

been less mild to skin than non-antimicrobial soaps; however, the latest generation of antimicrobial

Traditionally, antimicrobial soaps have been less mild to skin than non-antimicrobial soaps; however, the latest generation of antimicrobial soaps can provide antimicrobial efficacy as well as improved skin mildness.

soaps can provide antimicrobial efficacy as well as improved skin mildness. Choosing a well-formulated soap with low potential for irritation can help mitigate skin health issues and will be discussed later in this paper. But first, it's important to understand that choices around antimicrobial soaps may be limited in the future due to regulatory changes underway.

The Regulatory Landscape

The Food and Drug Administration (FDA) Division of Over-The-Counter Drug Products (OTC) regulates the use of antiseptic drug products used in healthcare. There are two regulatory pathways for these products; one is a New Drug Application (NDA) and one is the Monograph process. OTC Drug Monographs are a practical alternative to the FDA reviewing individual drugs on the market, as is the process with prescription drugs.

The Monograph Process

The monograph is a "recipe book" that specifies allowed ingredients, doses, and formulations and provides a set of labeling and testing requirements for manufacturers. There are three phases of the public rulemaking process that establish a Monograph.⁷

Phase 1: an FDA-appointed advisory review panel comprised of scientifically qualified experts evaluate data about the ingredients and classify them into three different categories:

- *Category I:* Generally recognized as safe and effective (GRASE)
- *Category II:* Not GRASE – these active ingredients cannot be marketed and sold
- *Category III:* Not enough data to make a final decision on safety and effectiveness, but sufficient data for the sale of products containing these active ingredients until the monograph is finalized.

Phase 2: the FDA evaluates information, including panel findings, public comments, and additional data that had become available and was eligible for inclusion. After this evaluation process, the agency publishes its tentative conclusions as proposed rules in the Federal Register. These are referred to as tentative final monographs (TFM). Once a TFM is published, manufacturers can develop and market products that comply with TFM requirements.

Phase 3: the FDA considers the comments and responses to the published TFM and new data received. Then, FDA publishes a final rule (called a final monograph) that establishes standards for both the active ingredients and the labeling in each OTC drug category. Upon publication of a final monograph, only active ingredients that are GRASE are included. Category I-III designations are no longer used and the final monograph is followed. This document is first published in the *Federal Register*, and later in the *Code of Federal Regulations*.

Regulatory Changes in Healthcare

The Monograph under which healthcare is currently operating has been in phase 2 (TFM) since 1994. The Healthcare OTC Monograph is not to be confused with the Consumer Monographs, which govern the active ingredients used in products marketed to consumers or made available for use in public settings.

or made available for use in public settings.⁸ The rule applies to antimicrobial soap products, not hand sanitizers or hand sanitizing wipes. It also does not apply to products used in the healthcare and food industries. The FDA lists active ingredients that can no longer be used in consumer antimicrobial soap products. This includes triclosan, one of the most common antimicrobial ingredients. Manufacturers have one year to comply with this rule by reformulating or removing these products from the market. The Consumer Hand Sanitizer Monograph is expected to publish in 2019 and the FDA requested the latest science supporting the safety and efficacy of these products in June 2016.

The Healthcare Monograph

The Healthcare Monograph is on a different timeline than the Consumer Monographs (**Table 4**). The FDA released a proposed rule, or an addendum to the Healthcare 1994 TFM on April 30, 2015. Within the proposed rule, the FDA called for more data on the safety and efficacy of active ingredients used in hand hygiene products and established a new, protocol-driven safety framework to ensure that hand hygiene ingredients used by HCW are both safe and effective. This framework did not exist in the previous OTC Monograph; therefore, all antiseptic ingredients' statuses were moved to a Category IIISE (designation for safety and effectiveness) by default.

Table 4. Consumer versus Healthcare Antiseptic Monograph Timeline

	Consumer Antiseptic Handwash Monograph	Healthcare Antiseptic Products Monograph
Scope: products	Antimicrobial soaps	Antimicrobial soaps and hand sanitizers
Scope: markets	Consumer settings, excludes healthcare	Healthcare settings only
TFM publication date	December 16, 2013	April 30, 2015
Final Monograph publication date	September 2, 2016	January 15, 2018

The Consumer Monographs

The Consumer Monograph is separated into two separate Monographs; one for soaps and one for hand sanitizers. On September 2, 2016, the FDA issued a final rule pertaining to active ingredients used in antibacterial soap products marketed to consumers

The FDA was clear that there was no indication of a potential problem with efficacy or safety; rather because many changes and advances have occurred since the FDA began review of health care antiseptics in the 1970s such as frequency of product use, new technology that can detect low levels of

antiseptics in the body, and scientific knowledge about the impact of widespread antiseptic use, the FDA has requested more data on active ingredients.⁹

Based on their review of the safety and efficacy studies, the FDA will make a final decision about which actives ingredients will continue to be permitted for use in hand hygiene products. Ethyl alcohol, PCMX, benzalkonium chloride, and benzethonium chloride have been granted deferrals by the FDA in order to provide time for industry to complete additional safety and efficacy testing. FDA will not make a final ruling on the deferred ingredients in the upcoming January 2018 ruling; however, ethyl alcohol in particular is well-positioned to eventually be included in a final monograph as it has the least amount information needed to close any data gaps. Other actives such as triclosan will likely be eliminated in the January 2018 ruling by FDA and have a 1-year phase-out period. These upcoming changes may have a significant impact on a healthcare facility's decision about which soap to choose.

Alternative Regulatory Pathway – New Drug Application

There are hand hygiene products used in healthcare today that are not affected by upcoming Monograph changes because they have already been proven to be safe and effective. Products that contain active ingredients not included in the Monograph or combinations of active ingredients follow a different regulatory pathway. The New Drug Application (NDA) pathway is the vehicle through which drug sponsors (the person or entity who assumes responsibility for the marketing of a new drug) formally propose that the FDA approve a new pharmaceutical for sale and marketing in the U.S.¹⁰ The FDA reviews the application to determine whether the drug is safe and effective when used as proposed, whether the drug's labeling is appropriate, and whether the drug was manufactured in a way that maintains the quality of the drug. If the NDA is approved, then the drug may be marketed and sold in the U.S.

In the future, the use of CHG hand soaps may increase given its trusted efficacy, broad spectrum of activity, proof of safety and efficacy and as a result its regulatory stability as an NDA product.

As an example, chlorhexidine gluconate (CHG) is an active ingredient used in a variety of applications in healthcare today, including patient bathing, pre-operative skin preparation, impregnated dressings and a variety of other antiseptic uses to prevent colonization and infection by bacteria. CHG is not an active ingredient covered by the Monograph and therefore requires a NDA. In the future, the use of CHG hand soaps may increase given its trusted efficacy, broad spectrum of activity, proof of safety and efficacy and as a result its regulatory stability as an NDA product.

Choosing a Soap for Your Healthcare Facility

With all of the considerations around soap, selecting the right product can be confusing. Additionally, there can be reluctance to changing hand hygiene products in healthcare facilities due to the many considerations that go along with it, such as potential for a period of adjustment among HCW, the logistics involved with switching dispensers, and disruptions to the clinical workflow. When considering a product change or if you're currently using a soap active ingredient with an uncertain future, it's important to carefully select the right product and right dispensing solution for your facility.

Poorly formulated soap can have profound negative effects on HCW skin condition and can contribute to a cycle of skin damage that is reinforced by avoidance of ABHR and continued over-use of soap. Therefore, selecting well-formulated products is an important foundational aspect of a hand hygiene and an infection prevention and control program.

As previously discussed, soap has not been given as much consideration as ABHR when healthcare facilities have chosen hand hygiene products. Poorly formulated soap can have profound negative effects on HCW skin condition and can contribute to a cycle of skin damage that is reinforced by avoidance of ABHR and continued over-use of soap. Therefore, selecting well-formulated products is an important foundational aspect of a hand hygiene and an infection prevention and control program.

How to select the Right Soap for your Facility

Factors to consider when selecting soap for your healthcare facility are summarized in **Table 5**. Deciding whether to use an antimicrobial or a non-antimicrobial soap is often the first decision. Many healthcare facilities take a risk-reduction approach by utilizing an antimicrobial soap for added protection, while some choose a hybrid approach and deploy antimicrobial soap to high acuity areas such as intensive care units, hematology-oncology areas, and surgical areas. Others use non-antimicrobial soaps throughout the facility. While the evidence around whether antimicrobial soaps result in better clinical outcomes remains elusive, it is estimated that as much as two-thirds of the soaps sold into healthcare today is antimicrobial, and triclosan represents over half of antimicrobial soaps.³ Therefore, there is a possibility that many healthcare facilities will be forced to make a switch in the coming years if certain actives are no longer permitted in soap.

Four Key Factors to Consider When Selecting a Soap

Developing a truly mild, yet effective soap that can be used multiple times during a HCW's shift is a significant technical challenge, so it's important to carefully assess products under consideration. It can be very helpful to evaluate soaps within the context of four important factors: efficacy, skin health, aesthetics (skin feel) and regulatory stability. It is important to note that more sensitive skin often undergoes a period of adjustment during which the skin's natural defenses better tolerate any product change that is made. As a result, trialing products for a minimum of two-three weeks is essential since the stratum corneum renewal time or "turnover" typically occurs in that timeframe.¹¹ If there are skin adjustment issues that occur during the beginning of a trial period, they should also subside within that two-to-three-week window. It is also advisable that if trialing more than one product back-to-back, a washout period of around one week between products is scheduled during which time the previous product is re-implemented. The WHO provides two protocols for evaluation of tolerability and acceptability of ABHR which can be adapted for soap evaluations.¹²

Efficacy. For antimicrobial soaps, it is not only important to consider different active ingredients,

but also evaluate the efficacy of finished formulations. The Healthcare Personnel Handwash Test is the only FDA-accepted test for healthcare hand wash products and it measures the reduction of a transient market organism (*Serratia marcescens*) on the hands of adult subjects after a single product use and after 10 consecutive product uses. The FDA requires antimicrobial hand wash and hand rub agents achieve a 2-log₁₀ reduction at Application 1 and a 3-log₁₀ reduction at Application 10.¹³ Product manufacturers should supply customers with this data for products being sold into healthcare.

Skin health. How a product affects the skin health of end-users is especially important in environments such as healthcare where repeated use scenarios are common. While the OTC Monograph does not specify irritancy testing requirements, ensuring skin tolerance of products is critical to maximizing HCW acceptance and hand hygiene compliance.¹ Industry standard is a 14-day human cumulative irritancy assay with delayed challenge. This type of study is designed to assess the irritation potential of test product and involves daily, consecutive application of product in "patches" to the forearm of human subjects for 14 days. A control material or product is also included in the study. Dermal reactions, including erythema, edema, and other features indicative of irritation, are scored by expert visual assessments using a standard scale. A mean cumulative irritation score on a scale of 0-4 is reported with lower numbers indicating lower potential for skin irritation and allergic contact dermatitis. Forearm controlled application tests are also used to determine irritation or skin improvement effects of products under more "real world" conditions over an extended period of time. The most important tests, however, are field or clinical tests that determine irritation or skin improvement effects of products with realistic conditions and behaviors in clinical settings.

Aesthetics/Skin Feel. Product aesthetics and skin feel are focused towards end-user acceptance. Aesthetic considerations can begin with how the product looks (color), the product form (foam or liquid), and the sensory experience during use which

Balancing efficacy, skin health, and skin feel can be difficult to accomplish, but with proper formulation, of both ABHRs and soaps, it is possible to achieve this balance.

it lathers and rinses. The bottom line is that if HCW do not like a product, they are less likely to use it,¹⁴ so aesthetic and skin feel considerations should not be minimized. Balancing efficacy, skin health, and skin feel can be difficult to accomplish, but with proper formulation, of both ABHRs and soaps, it is possible to achieve this balance.

Regulatory Stability. Lastly, regulatory stability may become a more important consideration as the regulatory landscape changes in the coming years.

Because changing products can be a challenging undertaking in healthcare and is often avoided whenever possible, choosing an active with greater regulatory stability can minimize or eliminate the possibility of a future product switch. NDA soap products have already gone through the process of ensuring safety and efficacy and will not be impacted by Monograph changes. **Table 5** summarizes other important factors to consider when selecting a soap for your healthcare facility.

Table 5. Factors to Consider when Selecting a Soap for a Healthcare Facility

Factor	Considerations
Antimicrobial vs. Non-Antimicrobial Soap	<ul style="list-style-type: none"> • Determine level of “risk tolerance” <ul style="list-style-type: none"> o For greatest risk reduction, choose an antimicrobial soap • Consider a single soap product approach or a hybrid approach (e.g. antimicrobial in high acuity areas only) <ul style="list-style-type: none"> o A hybrid approach can add complexity for Environmental Services (EVS)
Efficacy (Antimicrobial Soaps)	<ul style="list-style-type: none"> • Product should meet FDA efficacy requirements defined in OTC Monograph <ul style="list-style-type: none"> o Solicit product manufacturer for technical bulletin
Skin Health/Mildness	<ul style="list-style-type: none"> • Maintains skin condition with repeated use • Solicit skin health testing data from product manufacturer <ul style="list-style-type: none"> o <u>14 day irritancy test</u> is used to determine exaggerated irritant potential that may be cumulative with repeated exposure of a material. o <u>Forearm controlled application test</u> is used to determine irritation or skin improvement effects of products under more “real world” conditions over an extended period time. As part of this test, skin hydration, TEWL, skin erythema, redness and dryness and other measures may be conducted to evaluate product performance. • <u>Field or home-use tests</u> are used to determine irritation or skin improvement effects of products with realistic conditions & behaviors
Aesthetics (Skin Feel)	<ul style="list-style-type: none"> • Color <ul style="list-style-type: none"> o Color can be used to connote or visually depict features and benefits of the product (ex. aloe-containing products are often green and perceived as soothing) o Some facilities prefer dye-free products whenever possible • Format (foam vs. liquid) - this is purely a preference • Lather - product should have an acceptable lather • Rinse - product should rinse easily and leave behind a “clean feeling” • Scent/odor/fragrance <ul style="list-style-type: none"> o Fragrance can be a positive aspect of the sensory experience, and in one study had a positive effect on hand hygiene compliance.¹⁵ o Some facilities have a fragrance-free policy. o Fragrance is often used to minimize the base odor of raw ingredients and active ingredients which can often have an unpleasant odor. o Fragrance can either be synthetic or natural (e.g. essential oils). o If carefully selected, fragrance can be used in levels appropriate for the healthcare environment.

Table 5. Factors to Consider when Selecting a Soap for a Healthcare Facility (conti.)

Factor	Considerations
Dispensing Solutions	<ul style="list-style-type: none"> • Touch-free <ul style="list-style-type: none"> ◦ In one study, touch-free dispensers were used significantly more than manual dispensers and were associated with an increased hand hygiene compliance rate¹⁶ ◦ Believed to reduce cross-contamination by multiple users¹⁷ • Manual <ul style="list-style-type: none"> ◦ Allows for adjustment of amount of product dispensed, which may impact efficacy¹⁷ • Sealed container - products used in healthcare should come in sealed containers. Refilling bottles or “topping off” product is not acceptable practice in healthcare facilities.¹ • Environmental considerations – inquire with product manufacturer as to whether empty refills containers are recyclable. • Compatibility with Electronic Compliance Monitoring (ECM) technology – determine if dispensers are ECM-ready should upgrading to this technology be of future interest
Other Value Added Programs	<ul style="list-style-type: none"> • Education – inquire if the vendor offers education around their product in the form of in-services, peer-reviewed publications, or other materials.
Regulatory Stability	<ul style="list-style-type: none"> • There is uncertainty around the availability of some antimicrobial soap active ingredient when the OTC finalizes in the future • New Drug Application (NDA) – products that have undergone the NDA process will not be affected by changes to the Monograph
HCW acceptance	<ul style="list-style-type: none"> • Both the CDC and the WHO recommend soliciting input from HCW when selecting hand hygiene products to maximize acceptance. Ideally, HCW should be given the opportunity to trial products at minimum for two weeks. The WHO provides two product trial protocols for consideration.¹²
Product Compatibility and Known Interactions	<ul style="list-style-type: none"> • Solicit information from product manufacturer on product compatibility. Inquire about known interactions between products used to clean hands, skin care products, and type of gloves used.¹
Cost	<ul style="list-style-type: none"> • While cost is an important consideration for most healthcare facilities, it should not be the overriding factor when selecting a product.¹ If a product is not of acceptable quality, well-formulated, and liked by HCW, then it may not be used.

Conclusion

Because of the changing regulatory landscape, it is important for key decision makers to be armed with as much knowledge around soap as possible. Some soap active ingredients that are known and used today have uncertain futures and may not be available long-term. Although ABHR should remain the primary method for performing hand hygiene, soap continues to be an important piece of the hand hygiene regimen. Careful consideration should be given when selecting soap due to its potential for adverse skin effects if not properly formulated. Evaluating soap and ABHR in terms of efficacy, skin health, aesthetics/skin feel, and regulatory stability can be helpful. As always, allowing HCWs the opportunity to trial products and provide input is a critical aspect of product acceptance. While selecting the right soap may not be easy, being well-informed about the options and key selection factors can help make the process easier.

Reference List

1. Centers for Disease Control and Prevention. Guidelines for hand hygiene in health-care settings—2002. Recommendations of the Healthcare Infection Control Practices Advisory Committee and the HICPAC/SHEA/APIC/IDSA Hand Hygiene Task Force. *MMWR* 2002;51 (RR-16):1-45.
2. Dubberke ER, Carling P, Carrico R, et al; Society for Healthcare Epidemiology of America. Strategies to prevent *Clostridium difficile* infections in acute care hospitals: 2014 update. *Infect Control Hosp Epidemiol*. 2014;35(6):628-645.
3. Market share information derived through Global Healthcare Exchange, LLC dataset, 2015.
4. Widmer AF. Replace and washing with use of a waterless alcohol hand rub? *Clin Infect Dis*. 2000;31:136-43.
5. World Health Organization. WHO guidelines on hand hygiene in health care. First global patient safety challenge: clean care is safer care. http://whqlibdoc.who.int/publications/2009/9789241597906_eng.pdf. Published 2009. Accessed March 1, 2015.
6. Larson E, Girard R, Pessoa-Silva CL, Boyce J, Donaldson L, Pittet D, et al. Skin reactions related to hand hygiene and selection of hand hygiene products. *Am J Infect Control*. 2006;34:627-635.
7. Over-the-counter drug Monograph process. U.S. Food and Drug Administration Web site. <http://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ucm317137.htm>. Updated January 7, 2015. Accessed May 1, 2016.
8. FDA issues final rule on safety and effectiveness of antibacterial soaps: rule removes triclosan and triclocarben from over-the-counter antibacterial hand and body washes [news release]. Silver Spring, MD: U.S. Food and Drug Administration; September 2, 2016. <http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm517478.htm>. Accessed February 7, 2017.
9. FDA issues proposed rule to address data gaps for certain active ingredients in health care antiseptics: product use should continue in health care setting as additional data are gathered [news release]. Silver Spring, MD: U.S. Food and Drug Administration; April 30, 2015. <http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm445002.htm>. Accessed May 1, 2016.
10. New Drug Application (NDA). U.S. Food and Drug Administration Web site. <http://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/NewDrugApplicationNDA/>. Updated March 29, 2016. Accessed May 1, 2016.
11. Baker H. Technique for estimating turnover time of human stratum corneum. *J Am Med Assoc*. 1967;95(4):408-411.
12. Clean care is safer care: tools for evaluation and feedback. Centers for Disease and Prevention Web site. http://www.who.int/gpsc/5may/tools/evaluation_feedback/en/ Accessed May 1, 2016.
13. Department of Health and Human Services Food and Drug Administration (FDA). Tentative final monograph for health-care antiseptic drug products; proposed rule. *Federal Register*. 1994;59(116):31402-31452.
14. The Joint Commission. Measuring hand hygiene adherence: overcoming the challenges. Oakbrook Terrace, IL: The Joint Commission; 2009.
15. Birnbach DJ, King D, Vlaev I, Rosen LF, Harvey PD. Impact of environmental olfactory cues on hand hygiene behaviour in a simulated hospital environment: a randomized study. *J Hosp Infect*. 2013;85(1):79-81.
16. Larson EL, Albrecht S, O'Keef M. Hand hygiene behavior in a pediatric emergency department and a pediatric intensive care unit: comparison of use of 2 dispenser systems. *Am J Crit Care Nurses*. 2005;14:304-311.
17. Landers T. Hand hygiene products. In: Association of Professionals in Infection Control. *Guide to Hand Hygiene Programs for Infection Control*. 1st ed. Washington, DC: APIC; 2015.

Biography



Megan J. DiGiorgio, MSN, RN, CIC, FAPIC
Clinical Specialist, GOJO Industries

Megan has worked in infection prevention for over 10 years. She received her bachelors of science and masters of science in nursing from Case Western Reserve University in Cleveland, Ohio. Prior to her career in infection prevention she was a pediatric nurse. She has presented posters and oral abstracts at national conferences and has published in several peer-reviewed journals. Megan began working at GOJO in 2013. She became a fellow of the Association of Professionals in Infection Control (FAPIC) in 2016.